Ocular Surface Diseases, Disorders, and Dysfunctions®: Volume 5, Number 4

1.25 CME
1.00 COPE
75 MINS
$0 FEE
SAVE
Ocular Surface Diseases, Disorders, and Dysfunctions®: Volume 5, Number 4

Overview

Provider Statement

This continuing medical education activity is provided by Vindico Medical Education

This continuing education activity is provided by Purdue U


Support Statement

This activity is supported by an educational grant from Shire.


Activity Description

Early identification and prompt management of patients with ocular surface disease (OSD) can lessen disease severity and achieve earlier resolution. However, OSD continues to be challenging to differentially diagnose and therefore is frequently undertreated. Consequences of delayed identification and treatment of OSD have detrimental effects, but the continued assessment and refinement of diagnostic and management algorithms, along with advances in ocular imaging and therapeutic modalities, have the potential to enhance visual acuity outcomes and quality of life in patients with OSD. In this publication series, Ocular Surface Diseases, Disorders, & Dysfunctions®, Volume 5, expert clinicians will review and evaluate pertinent advances for the diagnosis, treatment, and management of patients with OSD, as well as offer clinical guidance for the optimal management of challenging case presentations.


Target Audience

The intended audience for this activity is ophthalmologists, optometrists, and other health care professionals involved in the treatment of patients with ocular surface disease.


Learning Objectives

Upon successful completion of the publication series, participants should be better able to:

  • Evaluate new methods and modalities that assist in the diagnosis of ocular surface and dry eye disease.
  • Investigate the use of dry eye therapies in specific patient populations to better understand the attributes and limitations of monotherapy and combination therapy in these patients.
  • Assess the management of dry eye disease and ocular surface disorders both preoperatively and postoperatively to improve surgical outcomes.

Chief Medical Editor

Terry Kim, MD
Professor of Ophthalmology
Duke University School of Medicine
Chief, Cornea and External Disease Division
Director, Refractive Surgery Service
Duke University Eye Center
Durham, NC


Associate Medical Editor

Paul M. Karpecki, OD, FAAO
Director, Cornea Services 
Kentucky Eye Institute
Lexington, KY


Editorial Board

Brandon D. Ayres, MD*
Cornea Service
Co-Director of Cornea Fellowship
Wills Eye Hospital
Philadelphia, PA

Marjan Farid, MD*
Associate Professor of Ophthalmology
Director of Cornea, Cataract, and Refractive Surgery
Gavin Herbert Eye Institute
University of California, Irvine
Irvine, CA

Preeya K. Gupta, MD*
Associate Professor of Ophthalmology
Duke University School of Medicine
Cornea, Cataract, and Refractive Surgery
Clinical Director, Duke Eye Center
Durham, NC

Christopher E. Starr, MD, FACS
Associate Professor of Ophthalmology
Director, Refractive Surgery
Director, Cornea Fellowship
Director, Ophthalmic Education
Weill Cornell Medicine
New York Presbyterian Hospital
New York, NY

* Also a Faculty Contributor for this issue.


Guest Contributor

Alice T. Epitropoulos, MD, FACS
Ophthalmic Surgeons and Consultants of Ohio
The Eye Center of Columbus
Clinical Assistant Professor
The Ohio State University Medical Center
Columbus, OH


Reviewers

Ashay Bhatwadekar, PhD, RPh
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Medical Writer

Valeria Zimmerman, PhD


Accreditation

Purdue University is approved by the Council on Optometric Practitioner Education (COPE) as an administrator/provider of continuing education (CE).

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Credit Designation

This enduring material is COPE-accredited for 1.0 continuing education credits and is approved for one (1) year from the date of original release, December 10, 2019 to December 10, 2020.

COPE ID #: 65826-AS
COPE Event #: 118648

Please consult your state’s Board of Optometry to determine if the CE credit may apply toward your CE requirement for license renewal.

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, December 10, 2019 to December 10, 2020.


How to Participate in This Activity and Obtain CE/CME Credit

To participate in this CE/CME activity, you must read the objectives, answer the pretest questions, read the articles, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Purdue University will issue a CE Certificate or Vindico Medical Education will issue an AMA PRA Category (1) Credit(s) certificate.


Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, reviewers, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

Editorial Board and Faculty report the following relationship(s)

Brandon D. Ayres, MD
Consulting Fee: Alcon, Allergan, Bausch + Lomb, Gore, MicroSurgical Technology, Omeros, Shire, Sight Sciences
Speakers Bureau: Alcon, Allergan, Shire

Alice T. Epitropoulos, MD, FACS
Intellectual Property/Patent: EpiGlare Tester
Consulting Fee: Abbott Medical Optics, Alcon, Allergan, Bausch + Lomb, Bio-Tissue, Dompè, Eyevance, Ocular Therapeutix, Omeros, Physician Recommended Nutriceuticals, Shire, Sight Sciences, Sun, TearLab, TissueTech
Speakers Bureau: Abbott Medical Optics, Alcon, Allergan, Bausch + Lomb, Bio-Tissue, Dompè, Eyevance, Ocular Therapeutix, Omeros, Physician Recommended Nutriceuticals, Shire, Sight Sciences, Sun, TearLab, TissueTech
Contracted Research: InSite Vision, MDbackline, TearSolutions
Ownership Interest: Eyevance
Grant/Research Support:Bausch + Lomb, Kala, Ocular Therapeutix, Physician Recommended Nutriceuticals, TearLab

Marjan Farid, MD
Consulting Fee: Allergan, CorneaGen, Dompé, EyePoint, Eyevance, J&J Vision, Kala, Takeda

Preeya K. Gupta, MD
Consulting Fee: Alcon, Allergan, Aurea, Bausch + Lomb, J&J Vision, Kala, NovaBay, Novartis, Ocular Science, Omeros, Shire, TearLab, TearScience, Zeiss

Paul M. Karpecki, OD, FAAO
Consulting Fee: Aerie, Alcon, Allergan, Akorn, Anthem, Avellino, Bausch + Lomb, Bio-Tissue, BlephEx, Bruder Healthcare, Cambium, DGH Technology, Essilor, eyeBrain, EyeGate, EyePoint, Eyevance, Focus Labs, Icare, Imprimis, Ivantis, Jobson Healthcare, J&J Vision, Konan, Lentechs, Maculogix, Nevakar, Notal Vision, Novaliq, Novartis, Oasis Medical, Ocular Sciences, Oculus, OcuMedic, OCuSOFT, Oyster Point, PECAA, Quark, Refocus Group, Reichert, Rendia, RxSight, ScienceBased Health, Sentiss, Shire, Sight Sciences, Sun, TLC, Topcon, Vmax, Zeiss
Contracted Research: Novartis, Shire, Sight Sciences
Ownership Interest: Bruder Healthcare, Ophthalmic Resources, Optometric Medical Solutions, Silk Technologies, Tarsus Medical, TearLab

Terry Kim, MD
Consulting Fee: Aerie, Alcon/Novartis, Allergan/Actavis, Avedro, Avellino Labs, Bausch + Lomb/Valeant, BlephEx, CoDa/Ocunexus Therapeutics, Kala, NovaBay, Ocular Therapeutix, Omeros, PowerVision, Presbyopia Therapies, Shire, Simple Contacts, TearLab, Zeiss
Ownership Interest: Avellino Labs, CorneaGen, Kala, NovaBay, Ocular Therapeutix, Omeros, Simple Contacts

Christopher E. Starr, MD, FACS
Consulting Fee: Alcon/Novartis, Allergan, BlephEx, Bruder, Dompé, EyePoint, Eyevance, Kala, Quidel, Shire, Sun, TearLab
Contracted Research: Shire
Ownership Interest: TearLab

Medical Writer reports the following relationship(s)

Valerie Zimmerman, PhD
No relevant financial relationships to disclose.

Reviewers report the following relationship(s)

Ashay Bhatwadekar, PhD, RPh
No relevant financial relationships to disclose.

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Purdue University and Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Purdue University and Vindico Medical Education, Office of Medical Affairs and Compliance.


Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.


Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Purdue University and Vindico Medical Education continuing education activities does not necessarily reflect the views and opinions of Purdue University and Vindico Medical Education. Neither Purdue University and Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.


CME/CE Questions?

Contact us at:
Purdue University: cmemda@purdue.edu or 765-496-1306
Vindico Medical Education: cme@vindicocme.com or 856-994-9400, ext. 504